Member Info for mol42

This I believe is the study mentioned in the year end presentation

mol

See rule 17

https://docs.londonstockexchange.com/sites/default/files/documents/AIM%20Rules%20for%20Companies%20%2801012021%29_1.pdf

In so far as it has info

Not obliged to ask share registrars re 3 % holders but rely on being notified by same

Rule 26 is only in relation to info received

mol

Attending as one of nine investment gurus

https://www.sharestock.co.uk/

jees - hasn't many here even after his massive recent additional 50000 shares investment

though i note that website updated for Steen and Adam

Stephen O'Hara 6,131,450 3.88%

Frederik Bruhn-Petersen 3,000,000 1.90%

Adam Reynolds 192,857 0.06%

Steen Andersen 125,450 0.04%

mol

2,169 followers

2h

The gut microbiome is a complex ecosystem of trillions of microorganisms, and it plays a pivotal factor in overall health. For organisations developing functional foods and supplements, a thorough and expert understanding of its influence is vital to consumer health and to the success of a business.

Key functions of the microbiome:

The microbiome aids in breaking down complex carbohydrates, synthesising vitamins (like K and B), and fermenting dietary fibers into short-chain fatty acids (SCFAs). SCFAs, such as butyrate, propionate, and acetate, are crucial energy sources for colonocytes and play signalling roles in inflammation and metabolism.

A significant portion of the immune system resides in the gut. The microbiome interacts with immune cells, training them to differentiate between beneficial and harmful microbes. Dysbiosis (an imbalance in the microbiome) is linked to immune disorders and increased susceptibility to pathogens.

The microbiome helps maintain the integrity of the intestinal barrier, preventing the leakage of harmful substances into the bloodstream. A compromised barrier is associated with systemic inflammation and various health conditions.  

The gut-brain axis highlights the bidirectional communication between the gut and the central nervous system. The microbiome influences neurotransmitter production, potentially affecting mood, cognition, and behaviour.

The microbiome plays a role in energy homeostasis, lipid metabolism, and glucose regulation. Imbalances in the gut flora are implicated in metabolic disorders like obesity, type 2 diabetes, and cardiovascular disease.

At Optibiotix, we understand the importance of developing targeted microbiome-modulating products with interventions and solutions that promote a healthy gut microbiome. Our formulations address the root cause of many health challenges and improve consumer well-being, such as cardiometabolic health, immune support, digestive wellness and weight management.

By using cutting-edge science and strain-specific research, we develop next-generation health solutions. Contact us to learn more.

therein lies the problem - 2nd sentence of first paragraph and in particular last 7 words- presumably written by our CEO which no doubt he believes

mol

I noted this 23rd May

but who is going to hold a non uk investor to account re uk plc aim rules?

nobody and if they were willing to put their name forward then no reason not to disclose in rns

so i don't expect a 3% rns

mind was a week ago

lol

mol

Oops appointed but confirmed Jan 2023 - Though I'm sure he was working on pbx whilst gardening (one of his passions i believe)

mol

He has been in place since June 2022. Hard to believe how the time has passed .

mol

I'm in full agreement with your post FriedmanSowell

as to turnover

In the opinion of the directors, the Group has one class of business, in three geographical areas being that of identifying and

developing microbial strains, compounds and formulations for use in the nutraceutical industry. The Group sells into three highly

interconnected markets, all costs assets and liabilities are derived from the UK location.

Revenue analysed by geographical market

Year ended Year ended

31 December 2024 31 December 2023

£’000 .....£’000

UK 34k .....65k

US 1,457k ....1,008k

Rest of world 392k ....600k

Total... 1,883k .....1,673k

During the reporting period one customer represented £1.4m, (74.3%) of Group revenues.

(2023: one customer generated £1.0m representing 59.8% of Group revenues)

hasn't steen done well --- not!

mol

Hi martinu

At present we can only take them at their word that no further equity raises of any sort are required - i still reserve judgement on that based on my experience re aim companies

bw

mol

As we know steen has forecast 10m turnover and 2m ebitda by 2028 so overheads expected to rise to 3m by then subject to margin remaining as is

mol

Apropos PBX FriedmanSowell

PROBIOTIX HEALTH PLC

Notice is hereby given that the Annual General Meeting of Probiotix Health Plc (the “Company”) will be held at the offices of Gerald

Edelman, 73 Cornhill, London EC3V 3QQ on 27 June 2025 at 11:00 for the following purposes:

1. To receive the Company’s Report and Accounts for the year ended 31 December 2024.

2. To re‐elect Adam Reynolds, who retires by rotation, as a Director.

3. To re‐elect Steen Anderson, who retires by rotation, as a Director.

4. To re‐elect Frederick Bruhn‐Petersen, who retires by rotation, as a Director.

5. To re‐appoint Gerald Edelman LLP as auditors of the Company and to authorise the Directors to determine their remuneration.

and will resolution 7 be passed this year? The resolution allowing Steen to issue shares other than to existing shareholders.

Special Business

To consider and, if thought fit, to pass the following resolutions as to the resolution numbered 6 as an Ordinary Resolution and as

to the resolution numbered 7 as a Special Resolution:

7. THAT, subject to and conditional upon the passing of resolution 6, the Directors be and they are hereby generally empowered

pursuant to Section 570 of the Act to allot equity securities (as defined in Section 560 of the Act) for cash pursuant to the

authority conferred under Resolution 6 above as if sub‐section 561(1) of the Act did not apply to such allotment, provided that

this power shall be limited to:‐

(a) the allotment of equity securities in connection with a rights issue or any pre‐emptive offer in favour of holders of ordinary

shares in the Company where the equity securities attributable to the respective interests of such holders are proportionate

(as nearly as maybe) to the respective numbers of ordinary shares held by them on the record date for such allotment

subject to such exclusions or other arrangements as the Directors may deem necessary or expedient to deal with fractional

entitlements or any legal or practical difficulties under the laws of, or the requirements of, any regulatory body or stock

exchange of any overseas territory or otherwise;

(b) the allotment (otherwise than pursuant to sub‐paragraph (a) above) of equity securities up to an aggregate nominal value

of £7,908.33 being 10% of the current issued share capital.

resoultion 6 relates to issuing shares to existing shareholders in first place

Will optibiotix be allowed to vote on any of the resolutions - previous year they were and did by proxy i believe along with seneca

not long to wait

6 can be passed and 7 not btw however 7 can only be passed if 6 passed

mol

PROBIOTIX HEALTH PLC

Notice is hereby given that the Annual General Meeting of Probiotix Health Plc (the “Company”) will be held at the offices of Gerald

Edelman, 73 Cornhill, London EC3V 3QQ on 27 June 2025 at 11:00 for the following purposes:

1. To receive the Company’s Report and Accounts for the year ended 31 December 2024.

2. To re‐elect Adam Reynolds, who retires by rotation, as a Director.

3. To re‐elect Steen Anderson, who retires by rotation, as a Director.

4. To re‐elect Frederick Bruhn‐Petersen, who retires by rotation, as a Director.

5. To re‐appoint Gerald Edelman LLP as auditors of the Company and to authorise the Directors to determine their remuneration.

and will resolution 7 be passed this year? The resolution allowing Steen to issue shares other than to existing shareholders.

Special Business

To consider and, if thought fit, to pass the following resolutions as to the resolution numbered 6 as an Ordinary Resolution and as

to the resolution numbered 7 as a Special Resolution:

7. THAT, subject to and conditional upon the passing of resolution 6, the Directors be and they are hereby generally empowered

pursuant to Section 570 of the Act to allot equity securities (as defined in Section 560 of the Act) for cash pursuant to the

authority conferred under Resolution 6 above as if sub‐section 561(1) of the Act did not apply to such allotment, provided that

this power shall be limited to:‐

(a) the allotment of equity securities in connection with a rights issue or any pre‐emptive offer in favour of holders of ordinary

shares in the Company where the equity securities attributable to the respective interests of such holders are proportionate

(as nearly as maybe) to the respective numbers of ordinary shares held by them on the record date for such allotment

subject to such exclusions or other arrangements as the Directors may deem necessary or expedient to deal with fractional

entitlements or any legal or practical difficulties under the laws of, or the requirements of, any regulatory body or stock

exchange of any overseas territory or otherwise;

(b) the allotment (otherwise than pursuant to sub‐paragraph (a) above) of equity securities up to an aggregate nominal value

of £7,908.33 being 10% of the current issued share capital.

resoultion 6 relates to issuing shares to existing shareholders in first place

Will optibiotix be allowed to vote on any of the resolutions - previous year they were and did by proxy i believe along with seneca

not long to wait

6 can be passed and 7 not btw however 7 can only be passed if 6 passed

mol

Maybe in a term account maturing post year end - we will see in next 6 mth accounts - however there still should be an instant access working capital interest bearing account which there doesn't seem to be

mol

Going forward I'm holding £4m Turnover to Breakeven in my head based on £2m costs (this year £1,733 exc £116k non recurring and round up to make things simple)

Also where did they have the surplus cash - in a current account?

as there is no interest received - unbelievable Mark!

mol

please note

18. related party disclosures and epecially probiotix denmark aps - steen is the only director as far as i know though it is a 100% subsidiary

as at 31 december 2024 the company directly held the following subsidiaries:

country of incorporation / nature of business / dormant or active and proportion of equity interest

probiotix limited health - foods - active - united kingdom -100% of ordinary shares

probiotix health denmark aps - health foods - active denmark - 100% of ordinary shares

probiotix health denmark aps was registered 6 february 2023, the registered office is transformervej 14 2860 søborg, denmark.

the company acquired its 100% interest in probiotix limited by way of a share for ************** on 11 february 2022.

18. related party disclosures

group

during the year to 31 december 2024 £54,165, (2023: £30,000) was paid to reyco limited for the services of adam reynolds as

director of probiotix health plc. the balance owing at the year end was nil.

during the year to 31 december 2024 £20,000, (2023: £20,000) was paid to marco caspani for his services as director of probiotix

health plc. the balance owing at the year end was nil.

at the year end £5,000 was accrued for fees owing to frederick bruhn‐petersen for directors fees for the period 8 october to

31 december 2024 (2023: nil)

during the year to 31 december 2024 £30,000, (2023: £59,799) was invoiced by optibiotix health plc for the services of stephen o’hara as director of optibiotix health plc. the balance owing at the year end was £7,500.

during the year optibiotix limited transactions with probiotix limited were as follows:‐

• £171,733 (2023: £490,786) for salaries and administration costs;

• £0.00 (2023: £67,701) income received on behalf of probiotix limited; and

• £202,948 (2023: £425,640) repayments received.

there was no interest charged during the year. the balance owing at the year end of £3,770 was paid after the year end.

during the year to 31 december 2024 the group purchased lpldl stock to the value of £751,781, (2023: £607,390) from centro sperimentale del latte srl, a company in which marco capsani is a director. at 31 december 2024 there was balance owing to centro sperimentale del latte srl of nil.

company

during the year to 31 december 2024 £26,336 (2023: £167,957) was paid to balin s.a.g.l for the services of mikkel hvid‐hansen as

director of probiotix health plc who resigned on 28 february 2024.

during the year £252,663 (2023: £249,832) was paid to probiotix denmark aps for the services of steen andersen as ceo of probiotix

health plc. the year end balance was nil.

during the year £524,578 (2023: £173,363) was paid to probiotix denmark aps for management fees and operating costs.

mol

I believe the tax calcuation within the accounts is wrong as they have ended up with corporation tax payable of £9000 in note sixteen

whereas see note 6 which rightfully states

6. Corporation Tax

No liability to UK corporation tax arose on ordinary activities for the year ended 31 December 2024 nor for the period ended

31 December 2023.

albeit it says corporation tax credits which as it is a charge to P&L is incorrectly worded

mol

Options

S P O’Hara - 3,000,000 @0.210

M Caspani - 500,000 @0.210

A Reynolds - 1,000,000 @0.210

S Andersen - 5,000,000 @0.095

The share options held by S P O’Hara, and A Reynolds were granted on 31 March 2022 and are exercisable at £0.21 at any time up 30 March 2032, 50% of which vest on a doubling of the share price to £0.42 and 50% on an annual turnover of £2.5m.

The share options held by M Caspani were granted on 31 March 2022 and are exercisable at £0.21 at any time up 30 March 2032, 1/3 of which vest on each of the 2‐4 anniversaries of the date of grant.

The share options held by S Andersen were granted on 10 February 2025 and are exercisable at £0.095 at any time up 18 February 2035, 50% vest when annual turnover reaches £2.5m, 50% vest on annual turnover of £5m.

mol

For completeness

Steen 124550 £9823

Adam 50000 £3940

M Brandt 188945 £14790

M Collingbourne 108907 £7896

M Liticheski 76780 £5494

I agree martinu a start but a disappointing one at that

mol

549082

Split as follows

Steen 124550

Adam 50000

Others

188945 £14790

108907 £7896

76780 £5494

mol

Https://www.personalcaremagazine.com/story/48386/croda-beauty-gives-suppliers-day-innovation-sneak-peak

mol